ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
VENCLEXTA, Low-Dose Cytarabine Combination Study for AML Does Not Meet Primary Endpoint
March 04, 2020AbbVie announced the VIALE-C (M16-043) trial of venetoclax (VENCLEXTA®) in combination with low-dose cytarabine (LDAC) versus LDAC in combination with placebo did not meet its primary endpoint of ... -
Global Patients Whining about the Production Suspension of the Cytarabine Manufacturer
July 01, 2019Manufacturing delayed due to the manufacturer’s overhaul; production suspension leading to a shortage in the world -
FDA Approves DAURISMO with Cytarabine for AML
December 28, 2018he U.S. Food and Drug Administration (FDA) approved DAURISMO (glasdegib), in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in ..... -
Final NICE green light for Pfizer’s Mylotarg
November 19, 2018Cost regulators for the NHS in England and Wales have now published final guidelines recommending Mylotarg, alongside daunorubicin and cytarabine
Pharma Sources Insight January 2025
